MOR - MorphoSys upgraded at Morgan Stanley Aveanna wins positive views; and more in today's analyst action

MorphoSys upgraded at Morgan Stanley citing the potential of MonjuviMorphoSys (MOR) has lost ~23.8% in the year so far. Noting that the pullback has brought the shares towards its bear case value, Morgan Stanley analysts have upgraded the stock to overweight from equal-weight.The price target increased by $1.00 to $28.00 per share indicates a premium of ~25.1%. The analysts led by James P Quigley notice Monjuvi “gaining traction in the community setting” which according to them could fuel the medium-term uptake.Monjuvi an FDA-approved therapy in combination with lenalidomide for adults with B-cell lymphoma brought $15.5M in sales in Q1 2021 making up ~27.3% of the company's top-line.Analysts turn bullish on Aveanna Recently IPO’ed Aveanna Healthcare (AVAH) has mostly received favorable ratings from Wall Street. Barclays has an overweight rating and the price target of $20.00 indicates a premium of ~70.1%.The analyst Steve Valiquette cites Aveanna management’s multi-decade track record in home health

For further details see:

MorphoSys upgraded at Morgan Stanley, Aveanna wins positive views; and more in today’s analyst action